Giannis Mountzios, Director of the 4th Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center, shared a post on LinkedIn:
“In ASCO26, I had the opportunity to present the data of a post-hoc, subgroup analysis on intracranial efficacy of Tarlatamab compared to 2nd-line chemotherapy in patients with SCLC experiencing disease progression during or after 1st-line platinum-based chemotherapy with or without an immune-checkpoint inhibitor:
- In ITT (N=509), Tarlatamab reduced the risk of CNS progression or death compared to chemotherapy by 46% (median CNS PFS NR vs 7.2 m, HR=0.54)
- In patients with baseline Brain Metastases (BM) confirmed by BICR per mRANO-BM criteria (67 on Tarla, 56 on Chemo, 75% irradiated) , Tarlatamab improved CNS CR rates (15% vs 5%), median duration of CNS CR (NR vs 6.3 months), median duration of CNS disease control and intracranial ORR rates ( 56% vs 38%).
- Among patients with BM at baseline, patients treated with Tarla had an improved mOS (13.9 months) compared to those treated with chemo (6.8 months, HR=0.51), reducing the risk of death by half.
Importantly, among patients treated with Tarla, those with baseline BM and those without had similar OS, suggesting that Tarla has the potential to overcome the historically poor prognosis of patients with BM from SCLC.
Happy to have been able to contribute to a more effective treatment for this devastating disease.”